Omidenepag isopropyl
Omlonti (omidenepag isopropyl) is a small molecule pharmaceutical. Omidenepag isopropyl was first approved as Omlonti on 2022-09-22. It is used to treat intraocular pressure in the USA. It is known to target prostaglandin E2 receptor EP2 subtype.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| ocular physiological phenomena | D009799 |
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| omlonti | New Drug Application | 2025-04-21 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| intraocular pressure | — | D007429 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
OMIDENEPAG ISOPROPYL, OMLONTI, SANTEN | |||
| 2027-09-22 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Omidenepag Isopropyl, Omlonti, Santen | |||
| 11666563 | 2039-07-16 | U-3454 | |
| 10774072 | 2035-06-10 | DP | |
| RE48183 | 2035-01-08 | DP | U-3454 |
| 9415038 | 2035-01-08 | DP | U-3454 |
| 10179127 | 2035-01-08 | DP | U-3454 |
| 10702511 | 2035-01-08 | DP | U-3454 |
| 10765750 | 2035-01-08 | DP | |
| 11197849 | 2035-01-08 | DP | U-3454 |
| 8648097 | 2029-10-13 | DS, DP | |
| 8685986 | 2029-10-13 | DP | |
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 4 | 3 | — | — | 7 |
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | 1 | 4 | 3 | — | — | 7 |
| Glaucoma | D005901 | EFO_0000516 | H40 | 1 | 4 | 3 | — | — | 7 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | 3 | 1 | — | — | 4 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Omidenepag isopropyl |
| INN | — |
| Description | Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension.
|
| Classification | Small molecule |
| Drug class | non-prostanoid prostaglandin receptor agonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)OC(=O)CNc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)n1 |
Identifiers
| PDB | — |
| CAS-ID | 1187451-19-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297666 |
| ChEBI ID | — |
| PubChem CID | 44230999 |
| DrugBank | DB15071 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
PTGER2
PTGER2
Organism
Homo sapiens
Gene name
PTGER2
Gene synonyms
NCBI Gene ID
Protein name
prostaglandin E2 receptor EP2 subtype
Protein synonyms
PGE receptor EP2 subtype, PGE2 receptor EP2 subtype, prostaglandin E receptor 2 (subtype EP2), 53kD, prostaglandin E receptor 2 (subtype EP2), 53kDa, Prostanoid EP2 receptor
Uniprot ID
Mouse ortholog
Ptger2 (19217)
prostaglandin E2 receptor EP2 subtype (Q62053)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 130 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
39 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use